Today: 11 November 2025
Subscribe
Browse Tag

Biotechnology

Galecto (GLTO) Soars on Damora Therapeutics Acquisition and $285M Financing: IND in 2026, Proof‑of‑Concept in 2027

Galecto (GLTO) Soars on Damora Therapeutics Acquisition and $285M Financing: IND in 2026, Proof‑of‑Concept in 2027

Galecto, Inc. (NASDAQ: GLTO) said this morning it completed the acquisition of Damora Therapeutics and closed a $284.9 million oversubscribed private placement, a one‑two punch that instantly refocuses the company on mutant calreticulin (mutCALR) therapies for myeloproliferative neoplasms (MPNs) and extends its cash runway into 2029. The announcement sent GLTO screaming higher in pre‑market trading. GlobeNewswire Key takeaways Why this matters for patients and investors Damora’s approach is aimed squarely at mutant calreticulin (mutCALR)—a well‑validated genetic driver in segments of essential thrombocythemia (ET) and myelofibrosis (MF). Targeting this neoantigen has attracted growing interest as researchers seek more disease‑modifying options beyond
10 November 2025
 ·  ·  ·  ·  · 
‘Yeast Survives Mars’ & ESA’s ‘Protein Out of Thin Air’: How Biology Is Rewriting the Mars Menu — and What It Means for Investors

‘Yeast Survives Mars’ & ESA’s ‘Protein Out of Thin Air’: How Biology Is Rewriting the Mars Menu — and What It Means for Investors

Key facts (updated Nov 5, 2025): The story: Biology is moving from thought experiment to flight plan Europe’s HOBI‑WAN pilot (Hydrogen‑Oxidizing Bacteria in Weightlessness As a source of Nutrition) is ESA’s clearest sign yet that microbial food production will be part of living off‑Earth. The agency says the demonstrator feeds a bacterial culture with stored gases (H₂, O₂, CO₂) to produce Solein, a protein‑rich powder that needs “neither farmland nor sunlight.” The ISS testbed will ride in a standard locker and includes safety‑critical gas‑injection cartridges because hydrogen/oxygen handling in microgravity must be fail‑safe. The first eight months build and validate
5 November 2025
 ·  ·  ·  · 
Off-the-Shelf CAR-T Triumph: Caribou’s Breakthrough Results Spark Stock Surge

Off-the-Shelf CAR-T Triumph: Caribou’s Breakthrough Results Spark Stock Surge

Caribou’s Game-Changing CAR-T Results Caribou Biosciences – a clinical-stage biotech focusing on genome-edited cell therapies – stunned the biotech world with new data on November 3, 2025, showcasing that its off-the-shelf CAR-T cell treatments can achieve remission rates on par with personalized CAR-T therapies statnews.com. In an early-morning webcast, Caribou revealed Phase 1 trial outcomes from two programs: vispa-cel for B-cell lymphoma and CB-011 for multiple myeloma tipranks.com. The headline: patients with aggressive blood cancers, who had exhausted other options, responded remarkably well to these donor-derived CAR-T infusions. Caribou reported multiple complete and durable remissions in both trials, exceeding what
3 November 2025
 ·  ·  ·  ·  · 
Illumina Stock Surges on Genomics Breakthroughs – What’s Next for ILMN?

Illumina Stock Rockets 20%+ After Blowout Quarter – What’s Next for ILMN?

Stock Price & Recent Performance Illumina’s stock has whipsawed in late 2025. After drifting near its 52-week lows (~$69 in late 2024), it ticked up to the mid-$90s by mid-October 2025. Following the Oct. 30 earnings report, ILMN exploded higher: by Oct. 31 it was trading around $120 ts2.tech marketbeat.com. (MarketBeat confirms ILMN closed $123.64 on 10/31, +24.9% for the day marketbeat.com.) TS2.tech notes that the stock was “around the high $110s–$120 range” on Oct. 31, a sharp jump from the mid-$90s “just days prior” ts2.tech. The surge was driven by the earnings beat (see below) and raised guidance. In
1 November 2025
 ·  ·  ·  · 
Rani Therapeutics (RANI) Stock Skyrockets ~200% on $1B Pharma Deal – Will the Rally Last?

Rani Therapeutics Stock Explodes on Obesity-Drug Breakthrough – Analysts Eye $10+ Targets

Stock Performance and Recent Movement Rani shares have exploded in the last month. On Oct 1, 2025 RANI traded around $0.50. A landmark collaboration announced Oct 17 with Japan’s Chugai (up to $1.085B deal) and a simultaneous $60M financing sent the stock soaring. Intraday Oct 17 it jumped from $0.47 to $2.39 (+248%) ts2.tech. By Oct 31 the stock closed at $2.20, a 51.7% gain on that day alone ts2.tech. This means RANI is up roughly +20% in the past week (from ~$1.82 on Oct 24 to $2.20) and about +330% in October investing.com investing.com.This rally propelled RANI well above
1 November 2025
 ·  ·  ·  ·  · 
Genenta Science Stock Skyrockets on Strategic Gene-Therapy Alliance – Is a $25 Price Target Next?

Genenta Science Stock Skyrockets on Strategic Gene-Therapy Alliance – Is a $25 Price Target Next?

Genenta’s Oct. 24 announcement ignited optimism. According to the official press release, Anemocyte will incorporate Genenta’s clinically validated LVV plasmid DNA platform (originating from Naldini’s research) into its production pipeline investing.com. “By making our clinically validated LVV plasmid DNA technology platform available to Anemocyte and its clients, we are contributing to the reliable and scalable development of advanced therapy programs across the industry,” said CEO Pierluigi Paracchi investing.com. Anemocyte’s CEO Marco Ferrari added that the deal ensures customers have access to “a robust, well-established platform” for cutting-edge cell therapies investing.com. In effect, the partnership helps Genenta and its clients secure
24 October 2025
 ·  ·  ·  ·  · 
Minerva Neurosciences Stock Skyrockets on $200M Lifeline for Schizophrenia Drug

Minerva Neurosciences Stock Skyrockets on $200M Lifeline for Schizophrenia Drug

Stock Soars on Major Funding News Minerva Neurosciences’ stock chart went vertical on Tuesday after the biotech announced an expansive financing deal that effectively triples the company’s market capitalization overnight marketbeat.com. In pre-market trading on Oct. 21, NERV stock jumped as much as 160% on the news gurufocus.com. The shares opened around $6–7 (up from ~$2.66 prior close) and oscillated near those levels through the day, ultimately marking a 52-week high of $6.97 marketbeat.com. By comparison, NERV had traded as low as $1.15 within the past year marketbeat.com, reflecting both the dramatic rebound and the extreme volatility inherent in this
21 October 2025
 ·  ·  ·  · 
SPRO Stock Skyrockets on Breakthrough Oral Antibiotic Data

SPRO Stock Skyrockets on Breakthrough Oral Antibiotic Data

Stock Performance stockanalysis.com stockanalysis.com Spero’s shares have roughly doubled this year, hitting around $2.29 on Oct 20, 2025. The stock has traded in a broad range ($0.51–$3.22 over 52 weeks) stockanalysis.com. Trading volume is light (hundreds of thousands of shares), and the stock’s beta (~1.46) indicates volatility. In recent days, SPRO has climbed on the back of the Phase 3 data. The 50-day moving average (~$2.03) and 200-day average (~$1.83) (see data marketbeat.com) suggest the trend has turned positive after the spring rally. Year-to-date, SPRO is up ~120%, well above the small-cap biotech average. Recent Developments gsk.com gsk.com At IDWeek
21 October 2025
 ·  ·  ·  ·  ·  · 
Biotech Breakthrough: GRAIL (GRAL) Stock Surges on New Cancer-Detection Data

GRAIL (GRAL) Rockets to Record High on Samsung Mega-Deal and Cancer Test Breakthrough

Samsung Partnership Sparks Stock Surge GRAIL, Inc. (NASDAQ: GRAL) shares soared to record highs this week after the company announced a strategic collaboration with Samsung. On October 16, GRAIL revealed a binding agreement in which Samsung C&T and Samsung Electronics will invest $110 million into GRAIL at $70.05 per share ts2.tech. In return, Samsung C&T gains exclusive rights to distribute GRAIL’s Galleri multi-cancer early detection blood test in South Korea, with plans to expand to Japan and Singapore ts2.tech. Samsung Electronics will explore technology tie-ups, integrating its digital health platforms and AI with GRAIL’s cancer-detection technology tradingview.com prnewswire.com. Investors cheered the
17 October 2025
 ·  ·  ·  ·  · 
Femasys (FEMY) Stock Soars 46% on Fertility Tech and FDA Milestones

Femasys (FEMY) Stock Soars 46% on Fertility Tech and FDA Milestones

Femasys’ stock surge on Oct. 16 mirrors growing investor interest in its reproductive healthcare pipeline. The company’s FemaSeed™ technology is designed to boost pregnancy rates by delivering sperm directly into the fallopian tube, and published trials report more than double the pregnancy rate of traditional intrauterine insemination globenewswire.com stocktitan.net. Femasys is positioning FemaSeed as a first-line, lower-cost infertility option ahead of IVF. Meanwhile, FemBloc offers a first-of-its-kind permanent birth control that creates a natural scar in the fallopian tubes, avoiding surgery ir.femasys.com ir.femasys.com. This week’s ASRM announcement – coinciding with broader fertility news – helped lift FEMY. Also on Oct. 16, national media reported an expected
16 October 2025
 ·  ·  ·  ·  · 
Origin Agritech’s SEED Stock Skyrockets 92% on China Seed Breakthroughs & Trade Buzz

Origin Agritech’s SEED Stock Skyrockets 92% on China Seed Breakthroughs & Trade Buzz

SEED Stock Soars on Market Momentum Origin Agritech’s stock skyrocketed this week, delivering eye-popping gains for investors. On Tuesday night, SEED shares surged over 92% in after-hours trading following a flurry of positive developments benzinga.com. The price spiked from the $1.40 range to roughly $2.76 in extended trading – nearly a doubling overnight. By Wednesday Oct. 15, the stock opened sharply higher before paring back to about $1.43 by mid-day investing.com, roughly flat from Tuesday’s official close of $1.44 benzinga.com. This explosive move came amid a broader rally in agricultural and biotech shares. U.S. political news turbocharged the sector: a
15 October 2025
 ·  ·  ·  ·  · 
1 2
Go toTop